A double blind, placebo-controlled randomized study to compare the safety and tolerability of GTS-21 (25 mg TID, 50 mg TID, 75 mg TID and 150 mg TID) when administered daily for 28 days to participants with probable Alzheimer's disease
Latest Information Update: 18 Sep 2021
At a glance
- Drugs GTS 21 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
Most Recent Events
- 19 Apr 2007 Biomarkers information updated
- 02 Feb 2007 New trial record.